Neoleukin Therapeutics (NASDAQ:NLTX) Given New $6.00 Price Target at Piper Sandler

Neoleukin Therapeutics (NASDAQ:NLTXGet Rating) had its price objective decreased by Piper Sandler from $25.00 to $6.00 in a research note published on Friday morning, The Fly reports.

Separately, Zacks Investment Research downgraded Neoleukin Therapeutics from a buy rating to a hold rating in a report on Friday, May 13th.

Shares of Neoleukin Therapeutics stock opened at $1.00 on Friday. Neoleukin Therapeutics has a 12 month low of $0.92 and a 12 month high of $11.10. The business has a fifty day simple moving average of $1.43 and a two-hundred day simple moving average of $3.11. The firm has a market capitalization of $42.50 million, a P/E ratio of -0.90 and a beta of 1.24.

Neoleukin Therapeutics (NASDAQ:NLTXGet Rating) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. As a group, equities analysts expect that Neoleukin Therapeutics will post -1.23 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC bought a new stake in Neoleukin Therapeutics in the 1st quarter worth about $27,000. Kestra Private Wealth Services LLC increased its holdings in Neoleukin Therapeutics by 100.0% in the 1st quarter. Kestra Private Wealth Services LLC now owns 24,000 shares of the company’s stock worth $45,000 after buying an additional 12,000 shares in the last quarter. Shay Capital LLC bought a new stake in Neoleukin Therapeutics in the 1st quarter worth about $52,000. Goldman Sachs Group Inc. increased its holdings in Neoleukin Therapeutics by 45.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 66,772 shares of the company’s stock worth $126,000 after buying an additional 20,875 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Neoleukin Therapeutics by 50.4% in the 1st quarter. Renaissance Technologies LLC now owns 1,268,969 shares of the company’s stock worth $2,386,000 after buying an additional 425,357 shares in the last quarter. Institutional investors own 58.02% of the company’s stock.

About Neoleukin Therapeutics (Get Rating)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Further Reading

The Fly logo

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.